Year: 2026 | Month: March | Volume: 16 | Issue: 3 | Pages: 220-225
DOI: https://doi.org/10.52403/ijhsr.20260327
Serum Visfatin Levels in Women with Newly Diagnosed Polycystic Ovarian Disease: A Cross-Sectional Study
Dharani M1, Shenbagadevi S2, Jothilakshmi M V3
1Assistant Professor, Department of Physiology, Government Medical College, Tiruvallur, Tamil Nadu, India
2Assistant Professor, Department of Physiology, Government Medical College, Dindigul, Tamil Nadu, India
3Assistant Professor, Department of Physiology, Government Medical College, Tiruvallur, Tamil Nadu, India
Corresponding Author: Dharani M
ABSTRACT
Background: Polycystic ovarian disease (PCOD) is a common endocrine disorder frequently associated with insulin resistance and metabolic dysfunction. Visfatin, a visceral adipocytokine, has been implicated in inflammation and glucose regulation.
Aim: To determine Serum Visfatin levels in newly diagnosed PCOD women and assess its relationship with body mass index (BMI).
Methods: A cross-sectional study was conducted involving 80 women (40 PCOD; 40 healthy controls). Anthropometric, hormonal, glycemic, insulin resistance index, and serum Visfatin levels were measured.
Results: Serum Visfatin was significantly increased in PCOD cases (39.25 ± 16.49 ng/mL) compared to controls (27.90 ± 8.21; p = 0.004). PCOD women also had significantly elevated LH, LH/FSH ratio, fasting glucose, insulin, and HOMA-IR (p < 0.001).
Conclusion: Serum Visfatin is significantly elevated in PCOD and correlates with metabolic dysfunction. It may serve as an early biomarker for insulin resistance and cardiometabolic risk in PCOD.
Key words: PCOD, Visfatin, HOMA-IR, Insulin Resistance, Adipocytokines